Molecular imaging firm Blue Earth Diagnostics is highlighting findings on the effect of standardized reader training for images acquired with its Axumin (fluciclovine F-18) PET radiopharmaceutical in men with prostate cancer.
The phase III study showed that reader training is effective in enabling physicians who are new to Axumin PET/CT image interpretation to replicate results from expert readers, the company said. Axumin is a PET tracer cleared by the U.S. Food and Drug Administration (FDA) for use in men with suspected prostate cancer recurrence based on elevated blood levels of prostate-specific antigen (PSA) following prior treatment.
The study was based on PET/CT images from the Axumin image database at Emory University. With standardized Axumin reader training, readers without prior experience were able to achieve acceptable diagnostic performance and reproducibility when using Axumin PET/CT to restage patients with biochemically recurrent prostate cancer, Blue Earth said.
The results are important as the product continues to be made available in new centers around the U.S., according to the company.
